Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Cold-Chain Handling and Transfer of Purified Bulk – V 2.0

Posted on By


Biosimilars: SOP for Cold-Chain Handling and Transfer of Purified Bulk – V 2.0


Standard Operating Procedure for Cold-Chain Handling and Transfer of Purified Bulk in Biosimilar Manufacturing

Department Biosimilars
SOP No. SOP/BS/192/2025
Supersedes SOP/BS/192/2022
Page No. Page 1 of 9
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To establish a validated, GMP-compliant procedure for handling and transferring biosimilar purified bulk drug substance (BDS) under cold-chain conditions to ensure product integrity during internal movement or dispatch to fill-finish facilities.

2. Scope

This SOP applies to all biosimilar purified bulk lots that require storage and transfer at refrigerated (2–8°C) or frozen (≤ –20°C) temperatures during transit between manufacturing, storage, and formulation areas.

3. Responsibilities

  • Production: Prepare and hand over purified bulk containers for cold-chain transfer.
  • Warehouse/Logistics: Validate cold chain packaging, ensure calibrated temperature monitoring devices, and maintain documentation.
  • QA: Approve readiness of consignment and verify records before dispatch.

4. Accountability

The Head of Supply Chain and Head of Quality Assurance are accountable for ensuring cold-chain processes maintain temperature specifications and comply with GMP requirements.

5. Procedure

5.1 Pre-Transfer Preparation

  1. Verify bulk product has passed all applicable in-process QC tests and QA release.
  2. Confirm labeling on containers includes product ID, batch number, storage condition (e.g., 2–8°C), and status (Released).
  3. Select pre-qualified cold boxes, gel packs, or validated passive shippers capable of maintaining temperature for the expected transfer duration.

5.2 Temperature Monitoring Setup

  1. Use calibrated data loggers placed at representative locations (e.g., center and periphery of payload).
  2. Activate temperature loggers and record device ID and calibration due date in Annexure-1.

5.3 Packaging and Loading

  1. Condition refrigerant packs at required temperatures (e.g., 2–8°C or –20°C) for minimum 24 hours prior to use.
  2. Assemble shipper per vendor’s packing instruction: refrigerant layer, product containers, buffer pads, and logger placement.
  3. Seal shipper with tamper-evident tape and label externally with:
    • “Refrigerated Product – Do Not Freeze”
    • Shipping location
    • Contact person

5.4 Transfer and Handover

  1. Transport shipper using clean, qualified trolley or vehicle maintaining recommended temperature range.
  2. Ensure transfer is completed within maximum hold time defined in the BMR or validation study.
  3. Receiver must verify outer condition, temperature logger status, and document observations in Annexure-2.

5.5 Deviation Handling

  1. If temperature excursions are recorded or packaging is compromised:
    • Quarantine affected shipment
    • Initiate deviation form (Annexure-3)
    • QA to assess product impact and disposition

6. Abbreviations

  • BDS: Bulk Drug Substance
  • GMP: Good Manufacturing Practice
  • QA: Quality Assurance
  • QC: Quality Control

7. Documents

  1. Temperature Logger Activation Log – Annexure-1
  2. Cold Chain Transfer Record – Annexure-2
  3. Temperature Excursion Report – Annexure-3

8. References

  • WHO TRS 961 – Model Guidance on Storage and Transport of Time- and Temperature-Sensitive Products
  • ICH Q1A – Stability Testing of New Drug Substances
  • FDA Guidance on Transporting Biologic Products

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Temperature Logger Activation Log

Date Logger ID Batch No. Storage Range Cal. Due Date Activated By
04/05/2025 TL-0221 BS-BULK-052 2–8°C 12/09/2025 Ajay Verma

Annexure-2: Cold Chain Transfer Record

Date Batch No. From To Start Temp End Temp Received By
04/05/2025 BS-BULK-052 Manufacturing Fill-Finish 5.0°C 5.1°C Sunita Reddy

Annexure-3: Temperature Excursion Report

Date Batch No. Excursion Detail Duration Disposition QA Reviewer
04/05/2025 BS-BULK-052 Exceeded 8.0°C 18 minutes Accepted – No impact Dr. Neha Rao

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Included logger documentation and passive shipper validation Regulatory Audit Compliance
See also  Biosimilars: SOP for Use of Raw Materials in GMP Batches - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: SOP Training During Equipment/Process Validation
Next Post: SOP for Ensuring Compliance with Health Canada’s Medical Device Regulations

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version